AzerbaijanTuberculosis profile
Population  2017 9.8 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.86 (0.81–0.9) 8.7 (8.2–9.2)
Mortality (HIV+TB only) 0.023 (0.017–0.031) 0.24 (0.17–0.31)
Incidence  (includes HIV+TB) 6.5 (5–8.3) 67 (51–84)
Incidence (HIV+TB only) 0.11 (0.071–0.16) 1.1 (0.72–1.6)
Incidence (MDR/RR-TB)** 2.1 (1.5–2.8) 22 (16–28)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.36 (0.34–0.38) 2 (1.7–2.2) 2.3 (2–2.7)
Males 0.4 (0.38–0.43) 3.8 (3.1–4.5) 4.2 (3.4–5)
Total 0.77 (0.7–0.83) 5.8 (4.4–7.1) 6.5 (5–8.3)
TB case notifications, 2017  
Total cases notified 7 129
Total new and relapse 5 231
          - % tested with rapid diagnostics at time of diagnosis 55%
          - % with known HIV status 83%
          - % pulmonary 80%
          - % bacteriologically confirmed among pulmonary 74%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.14 (0.1–0.17)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 95 2%
          - on antiretroviral therapy 79 83%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 300
(1 200–1 300)
Estimated % of TB cases with MDR/RR-TB 12% (11–14) 28% (27–30)  
% notified tested for rifampicin resistance 54% 86% 4 908
MDR/RR-TB cases tested for resistance to second-line drugs   614
Laboratory-confirmed cases MDR/RR-TB: 1 007, XDR-TB: 118
Patients started on treatment **** MDR/RR-TB: 858, XDR-TB: 182
Treatment success rate and cohort size Success Cohort
New cases registered in 2016 84% 1 464
Previously treated cases registered in 2016 74% 2 220
HIV-positive TB cases registered in 2016    
MDR/RR-TB cases started on second-line treatment in 2015 59% 800
XDR-TB cases started on second-line treatment in 2015    
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 52%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
98% (72–100)
TB financing, 2018  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-09-25 Data: www.who.int/tb/data